Health Catalyst, Inc.(HCAT)— Stock Profile, AI Score & Financials

Technology · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Health Catalyst, Inc. (HCAT) stock profile, AI quality score, and SEC EDGAR financial data, a Technology sector company. 13F Pro's AI-powered ranking engine scores HCAT at 21.9/100 on a 32-signal composite quality model, placing it at rank #2,757 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (3.1) and institutional flow (6.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Health Catalyst, Inc. reports quarterly revenue of $70.5M, net income of $-40.5M, free cash flow of $-70.0K. Top institutional holders of HCAT by reported 13-F value include First Light Asset Management, CDC Financial, Palogic Value Management, L.P., based on the most recent SEC filings. HCAT trades on the Nasdaq exchange and files with the SEC under CIK 1636422. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HCAT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Health Catalyst, Inc. directly from SEC EDGAR.